maradonna 8888 / Shutterstock.com
The English Court of Appeal has issued the latest ruling in the patent dispute between Warner-Lambert and Actavis concerning Lyrica (pregabalin), says Arty Rajendra of Rouse Legal.
At 10:30am on June 29, a London court room packed full of patent lawyers will fall silent as the trial in Warner-Lambert v Actavis commences.
This case has already attracted significant media attention because it will determine how generic manufacturers market drugs for which the primary patent protection has expired but a second medical use patent for the drug remains valid.
Warner-Lambert, owned by pharmaceutical company Pfizer, markets the drug pregabalin under the brand name Lyrica.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Warner-Lambert, Actavis, patent, patent infringement, medical use, pregabalin,